Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$38.90
Price+1.70%
$0.65
1Y
Price
Market Cap
$3.104b
Mid
Price/Earnings 3y Avg5y Avg
36x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+21.1%
EBITDA Margin+20.6%
Net Profit Margin+23.2%
Free Cash Flow Margin+21.1%
EBITDA Margin+20.6%
Net Profit Margin+23.2%
Free Cash Flow MarginRevenue
$541.743m
+4.8%
1y CAGR+14.7%
3y CAGR+16.5%
5y CAGREarnings
$88.013m
+32.6%
1y CAGR+113.3%
3y CAGR+59.1%
5y CAGREPS
$1.08
+31.7%
1y CAGR+108.9%
3y CAGR+56.7%
5y CAGRBook Value
$1.344b
$1.436b
Assets$91.994m
Liabilities$39.333m
DebtDebt to Assets
2.7%
0.4x
Debt to EBITDAFree Cash Flow
$154.807m
+22.3%
1y CAGR+69.0%
3y CAGR+921.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company